Research
Hormonal
Gluteal-femoral subcutaneous adipose tissue in women acts as a safe lipid reservoir and actively regulates systemic metabolism, contributing to improved insulin sensitivity and lipid profiles compared to visceral fat.
Your body is designed to store fat in your hips and thighs to protect your metabolic health. This storage helps manage blood sugar and lipids better than storing fat in the abdomen. Embrace your body's natural storage pattern as a health asset.
GoodSupportsHIGH confidence
Gluteal-femoral adipose tissues of women may simply provide a safe lipid reservoir for excess energy, or they may directly regulate systemic metabolism via release of metabolic products or adipokines.
Why this rating
Supported by multiple studies on LPL activity, lipolysis, and adipokine levels, though some cellular mechanisms are still being investigated.
Source
Sex differences in human adipose tissues – the biology of pear shape
Kalypso Karastergiou et al. · Biology of Sex Differences · 2012
DOI 10.1186/2042-6410-3-13
narrative_reviewCited 1,096×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Women exhibit a 'pear-shaped' peripheral fat distribution (gluteal-femoral) that confers protection against metabolic diseases, including type 2 diabetes and atherosclerosis, independent of total body fat levels.Good
- Sex steroids (estrogen and testosterone) are the primary drivers of sex differences in fat distribution, with estrogen promoting peripheral storage and testosterone promoting central storage.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →